Uli Brödl, MD

Head of Research & Development, Chief Scientific Officer, Member of the Corporate Executive Board

Uli Brödl, MD, Head of R&D, Chief Scientific Officer, Grünenthal

Uli Brödl, MD, Head of R&D, Chief Scientific Officer

“We are committed to developing innovative treatment options for patients with pain. Together with my team, I strive to bring the best science forward.”

Uli Brödl, MD,

Head of R&D, Chief Scientific Officer

Uli Brödl, MD, assumed the role of Head of Research & Development, Chief Scientific Officer and Member of the Corporate Executive Board in February 2025. He has more than 15 years of industry experience and joined Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee.

In his most recent roles, Uli oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.

Uli Brödl at a glance


Nationality: German

Year of birth: 1972

Education: Medical Doctor at Ludwig-Maximilians University Munich; board-certified internist and endocrinologist at Klinikum Grosshadern in Munich and Adjunct Professor for Internal Medicine at the Ludwig-Maximilians University Munich

Family status: Married, three children

Leisure time: Running, skiing and playing the piano


Career highlights

Since 2025: Head of Research & Development, Chief Scientific Officer, Member of the Corporate Executive Board; Grünenthal

2020-2025: Head of Global Clinical Development & Operations, Member of the Bi Venture Fund Investment Committee; Boehringer Ingelheim

2017-2020: Country Medical Director and Vice President Medical and Regulatory Affairs; Boehringer Ingelheim Canada Ltd., Founder and Co-Chair BI Canada Incubator

2009-2016: Global Head Late Clinical Development, TA Metabolism, Boehringer Ingelheim

2008: German Board Certification in Endocrinology, Diabetes and Metabolism; Ludwig-Maximilians-Universität (LMU) Munich

2007: German Board Certification in Internal Medicine; Ludwig-Maximilians-Universität (LMU) Munich